

Table 1.108C Any Use and Misuse of Prescription Stimulant Subtypes in Past Year: Among People Aged 12 or Older; Misuse of Prescription Stimulant Subtypes in Past Year: Among Past Year Any Users of Prescription Stimulant Subtypes Aged 12 or Older; Standard Errors of Numbers in Thousands, 2019 and 2020

Stimulant Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse in Past Year among Total Population		Misuse in Past Year among Past Year Any Users of Stimulant Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Stimulant Subtypes (2020)
			(2019)	(2020)	(2019)	(2020)
ANY PRESCRIPTION STIMULANT	387	<i>603</i>	178	<i>292</i>	182	<i>292</i>
Amphetamine or Methylphenidate Products	340	<i>530</i>	173	<i>277</i>	176	<i>276</i>
Amphetamine Products	317	<i>501</i>	167	<i>284</i>	170	<i>283</i>
Methylphenidate Products	157	<i>284</i>	64	<i>113</i>	64	<i>113</i>
Anorectic (Weight-Loss) Stimulants	141	<i>267</i>	42	<i>86</i>	42	<i>86</i>
Provigil®	69	<i>109</i>	28	<i>54</i>	*	*
Any Other Prescription Stimulant ¹	158	<i>274</i>	10	<i>37</i>	10	<i>37</i>

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

¹ Includes use or misuse of stimulants containing other active ingredients. Reports of misuse of “any other prescription stimulant” that correspond only to the specific stimulant categories shown in the table are excluded from estimates for Any Other Prescription Stimulant and are included instead in the relevant stimulant category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

Table 1.108D Any Use and Misuse of Prescription Stimulant Subtypes in Past Year: Among People Aged 12 or Older; Misuse of Prescription Stimulant Subtypes in Past Year: Among Past Year Any Users of Prescription Stimulant Subtypes Aged 12 or Older; Standard Errors of Percentages, 2019 and 2020

Stimulant Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse in Past Year among Total Population		Misuse in Past Year among Past Year Any Users of Stimulant Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Stimulant Subtypes (2020)
			(2019)	(2020)	(2019)	(2020)
ANY PRESCRIPTION STIMULANT	0.14	<i>0.22</i>	0.06	<i>0.11</i>	0.85	<i>1.35</i>
Amphetamine or Methylphenidate Products	0.12	<i>0.19</i>	0.06	<i>0.10</i>	1.02	<i>1.58</i>
Amphetamine Products	0.12	<i>0.18</i>	0.06	<i>0.10</i>	1.09	<i>1.75</i>
Methylphenidate Products	0.06	<i>0.10</i>	0.02	<i>0.04</i>	1.77	<i>2.68</i>
Anorectic (Weight-Loss) Stimulants	0.05	<i>0.10</i>	0.02	<i>0.03</i>	1.79	<i>2.94</i>
Provigil®	0.03	<i>0.04</i>	0.01	<i>0.02</i>	*	*
Any Other Prescription Stimulant ¹	0.06	<i>0.10</i>	0.00	<i>0.01</i>	0.41	<i>1.33</i>

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

¹ Includes use or misuse of stimulants containing other active ingredients. Reports of misuse of “any other prescription stimulant” that correspond only to the specific stimulant categories shown in the table are excluded from estimates for Any Other Prescription Stimulant and are included instead in the relevant stimulant category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

Table 1.109C Any Use and Misuse of Prescription Stimulant Subtypes in Past Year: Among People Aged 12 to 17; Misuse of Prescription Stimulant Subtypes in Past Year: Among Past Year Any Users of Prescription Stimulant Subtypes Aged 12 to 17; Standard Errors of Numbers in Thousands, 2019 and 2020

Stimulant Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse in Past Year among Total Population		Misuse in Past Year among Past Year Any Users of Stimulant Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Stimulant Subtypes (2020)
			(2019)	(2020)	(2019)	(2020)
ANY PRESCRIPTION STIMULANT	67	<i>138</i>	37	<i>50</i>	37	<i>51</i>
Amphetamine or Methylphenidate Products	65	<i>130</i>	36	<i>48</i>	37	<i>48</i>
Amphetamine Products	58	<i>107</i>	35	<i>47</i>	35	<i>48</i>
Methylphenidate Products	39	<i>82</i>	15	<i>19</i>	15	<i>19</i>
Anorectic (Weight-Loss) Stimulants	15	<i>13</i>	7	<i>5</i>	*	*
Provigil®	5	<i>9</i>	2	<i>*</i>	*	*
Any Other Prescription Stimulant ¹	31	<i>53</i>	8	<i>15</i>	8	*

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

¹ Includes use or misuse of stimulants containing other active ingredients. Reports of misuse of “any other prescription stimulant” that correspond only to the specific stimulant categories shown in the table are excluded from estimates for Any Other Prescription Stimulant and are included instead in the relevant stimulant category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

Table 1.109D Any Use and Misuse of Prescription Stimulant Subtypes in Past Year: Among People Aged 12 to 17; Misuse of Prescription Stimulant Subtypes in Past Year: Among Past Year Any Users of Prescription Stimulant Subtypes Aged 12 to 17; Standard Errors of Percentages, 2019 and 2020

Stimulant Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse	Misuse	Misuse	Misuse
			in Past Year among Total Population (2019)	in Past Year among Total Population (2020)	in Past Year among Any Users of Stimulant Subtypes (2019)	in Past Year among Any Users of Stimulant Subtypes (2020)
ANY PRESCRIPTION STIMULANT	0.27	0.55	0.15	0.20	1.65	2.71
Amphetamine or Methylphenidate Products	0.26	0.52	0.14	0.19	1.78	2.97
Amphetamine Products	0.23	0.43	0.14	0.19	2.13	4.02
Methylphenidate Products	0.16	0.33	0.06	0.08	2.27	3.06
Anorectic (Weight-Loss) Stimulants	0.06	0.05	0.03	0.02	*	*
Provigil®	0.02	0.04	0.01	*	*	*
Any Other Prescription Stimulant ¹	0.12	0.21	0.03	0.06	2.08	*

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

¹ Includes use or misuse of stimulants containing other active ingredients. Reports of misuse of “any other prescription stimulant” that correspond only to the specific stimulant categories shown in the table are excluded from estimates for Any Other Prescription Stimulant and are included instead in the relevant stimulant category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

Table 1.110C Any Use and Misuse of Prescription Stimulant Subtypes in Past Year: Among People Aged 18 or Older; Misuse of Prescription Stimulant Subtypes in Past Year: Among Past Year Any Users of Prescription Stimulant Subtypes Aged 18 or Older; Standard Errors of Numbers in Thousands, 2019 and 2020

Stimulant Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse in Past Year among Total Population		Misuse in Past Year among Past Year Any Users of Stimulant Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Stimulant Subtypes (2020)
			(2019)	(2020)	(2019)	(2020)
ANY PRESCRIPTION STIMULANT	379	588	173	288	177	287
Amphetamine or Methylphenidate Products	330	<i>506</i>	167	<i>272</i>	170	<i>270</i>
Amphetamine Products	305	<i>480</i>	162	<i>279</i>	164	<i>278</i>
Methylphenidate Products	151	<i>269</i>	61	<i>111</i>	61	<i>110</i>
Anorectic (Weight-Loss) Stimulants	140	<i>267</i>	41	<i>86</i>	41	<i>86</i>
Provigil®	69	<i>108</i>	28	<i>54</i>	*	*
Any Other Prescription Stimulant ¹	155	<i>269</i>	7	<i>34</i>	7	<i>34</i>

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

¹ Includes use or misuse of stimulants containing other active ingredients. Reports of misuse of “any other prescription stimulant” that correspond only to the specific stimulant categories shown in the table are excluded from estimates for Any Other Prescription Stimulant and are included instead in the relevant stimulant category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

Table 1.110D Any Use and Misuse of Prescription Stimulant Subtypes in Past Year: Among People Aged 18 or Older; Misuse of Prescription Stimulant Subtypes in Past Year: Among Past Year Any Users of Prescription Stimulant Subtypes Aged 18 or Older; Standard Errors of Percentages, 2019 and 2020

Stimulant Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse		Misuse in Past Year among Past Year Any Users of Stimulant Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Stimulant Subtypes (2020)
			in Past Year among Total Population (2019)	in Past Year among Total Population (2020)		
ANY PRESCRIPTION STIMULANT	0.15	<i>0.23</i>	0.07	<i>0.11</i>	0.92	<i>1.47</i>
Amphetamine or Methylphenidate Products	0.13	<i>0.20</i>	0.07	<i>0.11</i>	1.13	<i>1.74</i>
Amphetamine Products	0.12	<i>0.19</i>	0.06	<i>0.11</i>	1.18	<i>1.89</i>
Methylphenidate Products	0.06	<i>0.11</i>	0.02	<i>0.04</i>	2.08	<i>3.12</i>
Anorectic (Weight-Loss) Stimulants	0.06	<i>0.11</i>	0.02	<i>0.03</i>	1.83	<i>2.97</i>
Provigil®	0.03	<i>0.04</i>	0.01	<i>0.02</i>	*	*
Any Other Prescription Stimulant ¹	0.06	<i>0.11</i>	0.00	<i>0.01</i>	0.32	<i>1.34</i>

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

¹ Includes use or misuse of stimulants containing other active ingredients. Reports of misuse of “any other prescription stimulant” that correspond only to the specific stimulant categories shown in the table are excluded from estimates for Any Other Prescription Stimulant and are included instead in the relevant stimulant category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

Table 1.111C Any Use and Misuse of Prescription Stimulant Subtypes in Past Year: Among People Aged 18 to 25; Misuse of Prescription Stimulant Subtypes in Past Year: Among Past Year Any Users of Prescription Stimulant Subtypes Aged 18 to 25; Standard Errors of Numbers in Thousands, 2019 and 2020

Stimulant Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse in Past Year among Total Population		Misuse in Past Year among Past Year Any Users of Stimulant Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Stimulant Subtypes (2020)
			(2019)	(2020)	(2019)	(2020)
ANY PRESCRIPTION STIMULANT	134	<i>198</i>	93	<i>121</i>	102	<i>127</i>
Amphetamine or Methylphenidate Products	132	<i>197</i>	92	<i>120</i>	102	<i>127</i>
Amphetamine Products	129	<i>190</i>	92	<i>116</i>	101	<i>122</i>
Methylphenidate Products	61	<i>88</i>	34	<i>42</i>	34	<i>42</i>
Anorectic (Weight-Loss) Stimulants	25	<i>43</i>	9	<i>8</i>	*	*
Provigil®	13	<i>10</i>	4	<i>5</i>	*	*
Any Other Prescription Stimulant ¹	34	<i>43</i>	7	<i>9</i>	7	*

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

¹ Includes use or misuse of stimulants containing other active ingredients. Reports of misuse of “any other prescription stimulant” that correspond only to the specific stimulant categories shown in the table are excluded from estimates for Any Other Prescription Stimulant and are included instead in the relevant stimulant category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

Table 1.111D Any Use and Misuse of Prescription Stimulant Subtypes in Past Year: Among People Aged 18 to 25; Misuse of Prescription Stimulant Subtypes in Past Year: Among Past Year Any Users of Prescription Stimulant Subtypes Aged 18 to 25; Standard Errors of Percentages, 2019 and 2020

Stimulant Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse in Past Year among Total Population		Misuse in Past Year among Past Year Any Users of Stimulant Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Stimulant Subtypes (2020)
			(2019)	(2020)	(2019)	(2020)
ANY PRESCRIPTION STIMULANT	0.40	<i>0.59</i>	0.27	<i>0.36</i>	1.47	<i>2.36</i>
Amphetamine or Methylphenidate Products	0.39	<i>0.59</i>	0.27	<i>0.36</i>	1.52	<i>2.45</i>
Amphetamine Products	0.38	<i>0.57</i>	0.27	<i>0.35</i>	1.60	<i>2.63</i>
Methylphenidate Products	0.18	<i>0.26</i>	0.10	<i>0.12</i>	2.83	<i>3.94</i>
Anorectic (Weight-Loss) Stimulants	0.08	<i>0.13</i>	0.03	<i>0.03</i>	*	*
Provigil®	0.04	<i>0.03</i>	0.01	<i>0.02</i>	*	*
Any Other Prescription Stimulant ¹	0.10	<i>0.13</i>	0.02	<i>0.03</i>	1.93	*

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

¹ Includes use or misuse of stimulants containing other active ingredients. Reports of misuse of “any other prescription stimulant” that correspond only to the specific stimulant categories shown in the table are excluded from estimates for Any Other Prescription Stimulant and are included instead in the relevant stimulant category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

Table 1.112C Any Use and Misuse of Prescription Stimulant Subtypes in Past Year: Among People Aged 26 or Older; Misuse of Prescription Stimulant Subtypes in Past Year: Among Past Year Any Users of Prescription Stimulant Subtypes Aged 26 or Older; Standard Errors of Numbers in Thousands, 2019 and 2020

Stimulant Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse in Past Year among Total Population		Misuse in Past Year among Past Year Any Users of Stimulant Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Stimulant Subtypes (2020)
			(2019)	(2020)	(2019)	(2020)
ANY PRESCRIPTION STIMULANT	344	<i>541</i>	138	<i>255</i>	139	<i>256</i>
Amphetamine or Methylphenidate Products	293	<i>448</i>	130	<i>236</i>	132	<i>237</i>
Amphetamine Products	271	<i>428</i>	128	<i>245</i>	129	<i>246</i>
Methylphenidate Products	134	<i>252</i>	49	<i>101</i>	49	<i>101</i>
Anorectic (Weight-Loss) Stimulants	136	<i>260</i>	40	<i>86</i>	40	<i>86</i>
Provigil®	68	<i>107</i>	27	<i>53</i>	*	*
Any Other Prescription Stimulant ¹	151	<i>265</i>	*	<i>32</i>	*	<i>32</i>

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

¹ Includes use or misuse of stimulants containing other active ingredients. Reports of misuse of “any other prescription stimulant” that correspond only to the specific stimulant categories shown in the table are excluded from estimates for Any Other Prescription Stimulant and are included instead in the relevant stimulant category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

Table 1.112D Any Use and Misuse of Prescription Stimulant Subtypes in Past Year: Among People Aged 26 or Older; Misuse of Prescription Stimulant Subtypes in Past Year: Among Past Year Any Users of Prescription Stimulant Subtypes Aged 26 or Older; Standard Errors of Percentages, 2019 and 2020

Stimulant Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse	Misuse	Misuse	Misuse
			in Past Year among Total Population (2019)	in Past Year among Total Population (2020)	in Past Year among Any Users of Stimulant Subtypes (2019)	in Past Year among Any Users of Stimulant Subtypes (2020)
ANY PRESCRIPTION STIMULANT	0.16	<i>0.25</i>	0.06	<i>0.12</i>	1.05	<i>1.71</i>
Amphetamine or Methylphenidate Products	0.14	<i>0.21</i>	0.06	<i>0.11</i>	1.38	<i>2.19</i>
Amphetamine Products	0.13	<i>0.20</i>	0.06	<i>0.11</i>	1.47	<i>2.40</i>
Methylphenidate Products	0.06	<i>0.12</i>	0.02	<i>0.05</i>	2.65	<i>4.02</i>
Anorectic (Weight-Loss) Stimulants	0.06	<i>0.12</i>	0.02	<i>0.04</i>	1.97	<i>3.18</i>
Provigil®	0.03	<i>0.05</i>	0.01	<i>0.02</i>	*	*
Any Other Prescription Stimulant ¹	0.07	<i>0.12</i>	*	<i>0.01</i>	*	<i>1.44</i>

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

¹ Includes use or misuse of stimulants containing other active ingredients. Reports of misuse of “any other prescription stimulant” that correspond only to the specific stimulant categories shown in the table are excluded from estimates for Any Other Prescription Stimulant and are included instead in the relevant stimulant category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.